1,209 trials (keyword fallback)
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) in Study Participants — 46 percentage of participants
Carcinoma, Hepatocellular
Primary: Incidence of Dose Limiting Toxicities (DLTs) — 1; 1; 2 Participants
Biliary Tract Neoplasms · Liver Cancer · Hepatocellular Carcinoma
Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months
Neuroendocrine Carcinoma · Islet Cell Carcinoma
Primary: Progression Free Survival (PFS) — 60 Weeks
Hepatocellular Carcinoma
Primary: Disease Control Rate (DCR) — 0; 0; 9 Participants
Carcinoma, Hepatocellular
Primary: Time to Progression-Blinded Independent Central Review (BICR) Assessment — 5.6; 4.1 Months — p=0.7382
Hepatocellular Carcinoma
Primary: Overall Survival (OS) — 9.17; 7.62 months — p=0.1391
Hepatocellular Carcinoma
Primary: One-Year Overall Survival Rate — 16 Participants
Hepatoma · Liver Neoplasms · Adenoma, Liver Cell
Primary: Phase I: Maximum Tolerated Dose (MTD) of TRC105 When Given With Standard-dose Sorafenib for Hepatocellular Cancer (HCC) — 15 mg/kg
Hepatocellular Carcinoma (HCC)
Primary: Overall Survival (OS) — 13.6; 12.3 months
Carcinoma, Hepatocellular · Gastric/Gastroesophageal Junction Cancer
Primary: Number of Participants With Adverse Events — 3; 24; 3; 78 Participants
Non-Small Cell Lung Cancer · Malignant Melanoma · Head and Neck Squamous Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/kg
Advanced or Metastatic Hepatocellular Cancer · Advanced or Metastatic Ovarian Cancer · Metastatic Renal Cell Cancer
Primary: Progression Free Survival (PFS) Rate, Defined as the Percentage of Patients Who Had Neither Progressed Nor Died as Measured by Centrally Analysed RECIST v1.1 (All…
Hepatocellular Cancer
Primary: Coagulation Zone Diameter-Short Axis — 36.0; 35.1 millimeters